Clinical Trial Update: Bryostatin 1 and Cisplatin in Treating Patients With Advanced Recurrent or Residual Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial of Bryostatin 1 in combination with Cisplatin for advanced recurrent or residual ovarian epithelial, fallopian tube, or primary peritoneal cancer …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fallopian Tube Cancer
• Ovarian Cancer
• Peritoneal Cancer

Drugs mentioned

• Bryostatin-1 (bryostatin-1)
• CISPLATIN (cisplatin)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Fallopian Tube Cancer, Primary Peritoneal Cavity Cancer | Phase 2 | Status: COMPLETED